

Anti-GITR [DTA-1] Bulk Size Ab01060-2.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric mouse antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Mouse IgG2a, Fc Silent™, Lambda

Clone Number: DTA-1

Alternative Name(s) of Target: CD357; AITR; GITR-D; Glucocorticoid-induced TNFR-related protein; TNFRSF18; Tumor necrosis factor receptor superfamily member 18

UniProt Accession Number of Target Protein: O35714

Published Application(s): agonist, IP, WB, FC

Published Species Reactivity: Mouse

Immunogen: This antibody was raised by immunising Wistar rats with the CD25+CD4+ T cell line. Hybridoma cells were generated by fusing spleen cells from the immunized rat with P3X63Ag8.653 myeloma cells, assessed for secreting antibodies capable of neutralizing in vitro CD25+CD4+ T cell-mediated suppression of anti-CD3-stimulated T cell proliferation⁹, and then cloned. This DTA-1 clone secreted a monoclonal rat immunoglobulin G2a (IgG2a) that showed high neutralizing activity.

Specificity: This antibody is specific for murine GITR, a member of the tumor necrosis factor receptor (TNFR) family that is expressed at low levels on unstimulated T cells, B cells, and macrophages. Upon activation, CD4+ and CD8+ T cells up-regulate GITR expression, whereas immunoregulatory T cells constitutively express high levels of GITR.

Application Notes: This antibody has been used in various FACS analyses for diverse immuno-oncological applications, such as to delineate how membrane-organizing protein moesin controls Treg differentiation and antitumor immunity via TGF- β signaling (Ansa-Addo et al, 2017), to suggest the therapeutic potential of TGF- β -induced Tregs (iTregs) in treating autoimmune gastritis (Nguyen et al, 2014), and to demonstrate that costimulation with the ligand of GITR elicits dose-dependent enrichment for cells of lower TCR affinity in the Treg cell repertoire (Mahmud et al, 2014). This antibody has also been used in Western Blots to elucidate the mechanism of human T-cell leukemia virus type 1 (HTLV-1) in the development of neoplastic and inflammatory diseases (Satou et al, 2011), and in immunoprecipitation analysis to aid the investigation of the role of GITR in dominant immunological self-tolerance maintained by CD25+CD4+ regulatory T cells (Shimizu et al, 2002). In addition, the anti-tumour effects of this agonistic anti-GITR antibody have been

demonstrated in various murine models (Scirka et al, 2017; Coe et al, 2010; Cohen et al. 2010; Hu et al, 2008; Ko et al, 2005).

Antibody First Published in: Shimizu Jun et al. Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002 Feb;3(2):135-42. [PMID:11812990](#)

Note on publication: Describe the original generation of this antibody and its subsequent applications in FACS, immunoprecipitation, in vitro and in vivo functional assays to show that GITR plays a key role in dominant immunological self-tolerance maintained by CD25+CD4+ regulatory T cells.

Product Form

Size: 1 mg Purified antibody in bulk size.

Purification: Protein A affinity purified

Supplied In: PBS only.

Storage Recommendation: Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.